vs
INTERPARFUMS INC（IPAR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
INTERPARFUMS INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$386.2M vs $207.3M），INTERPARFUMS INC净利率更高（7.3% vs -62.0%，领先69.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 6.8%），INTERPARFUMS INC自由现金流更多（$145.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.2%）
Inter Parfums Inc是全球知名的高端香水企业，开发、生产并销售多款授权香水、身体护理及相关美妆产品，与多家顶级奢侈时尚生活方式品牌合作推出联名香氛系列，产品覆盖全球主要市场，通过百货、美妆专营店及官方电商渠道触达消费者。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
IPAR vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.2M | $207.3M |
| 净利润 | $28.1M | $-128.6M |
| 毛利率 | 61.5% | — |
| 营业利润率 | 7.1% | -54.7% |
| 净利率 | 7.3% | -62.0% |
| 营收同比 | 6.8% | 25.9% |
| 净利润同比 | 16.0% | 3.5% |
| 每股收益（稀释后） | $0.88 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $386.2M | $207.3M | ||
| Q3 25 | $429.6M | $159.9M | ||
| Q2 25 | $333.9M | $166.5M | ||
| Q1 25 | $338.8M | $139.3M | ||
| Q4 24 | $361.5M | $164.6M | ||
| Q3 24 | $424.6M | $139.5M | ||
| Q2 24 | $342.2M | $147.0M | ||
| Q1 24 | $324.0M | $108.8M |
| Q4 25 | $28.1M | $-128.6M | ||
| Q3 25 | $65.8M | $-180.4M | ||
| Q2 25 | $32.0M | $-115.0M | ||
| Q1 25 | $42.5M | $-151.1M | ||
| Q4 24 | $24.2M | $-133.2M | ||
| Q3 24 | $62.3M | $-133.5M | ||
| Q2 24 | $36.8M | $-131.6M | ||
| Q1 24 | $41.0M | $-170.7M |
| Q4 25 | 61.5% | — | ||
| Q3 25 | 63.5% | — | ||
| Q2 25 | 66.2% | — | ||
| Q1 25 | 63.7% | — | ||
| Q4 24 | 64.5% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 64.5% | — | ||
| Q1 24 | 62.5% | — |
| Q4 25 | 7.1% | -54.7% | ||
| Q3 25 | 25.3% | -106.9% | ||
| Q2 25 | 17.7% | -64.8% | ||
| Q1 25 | 22.2% | -102.6% | ||
| Q4 24 | 10.0% | -74.3% | ||
| Q3 24 | 25.0% | -94.6% | ||
| Q2 24 | 18.9% | -79.1% | ||
| Q1 24 | 21.0% | -151.9% |
| Q4 25 | 7.3% | -62.0% | ||
| Q3 25 | 15.3% | -112.8% | ||
| Q2 25 | 9.6% | -69.0% | ||
| Q1 25 | 12.5% | -108.5% | ||
| Q4 24 | 6.7% | -80.9% | ||
| Q3 24 | 14.7% | -95.7% | ||
| Q2 24 | 10.8% | -89.5% | ||
| Q1 24 | 12.7% | -156.8% |
| Q4 25 | $0.88 | $-1.28 | ||
| Q3 25 | $2.05 | $-1.81 | ||
| Q2 25 | $0.99 | $-1.17 | ||
| Q1 25 | $1.32 | $-1.57 | ||
| Q4 24 | $0.78 | $-1.34 | ||
| Q3 24 | $1.93 | $-1.40 | ||
| Q2 24 | $1.14 | $-1.52 | ||
| Q1 24 | $1.27 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $137.1M | $421.0M |
| 总债务越低越好 | $176.0M | — |
| 股东权益账面价值 | $880.7M | $-80.0M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
| Q4 25 | $137.1M | $421.0M | ||
| Q3 25 | $77.5M | $202.5M | ||
| Q2 25 | $53.9M | $176.3M | ||
| Q1 25 | $75.3M | $127.1M | ||
| Q4 24 | $109.3M | $174.0M | ||
| Q3 24 | $78.8M | $150.6M | ||
| Q2 24 | $37.7M | $480.7M | ||
| Q1 24 | $76.1M | $112.3M |
| Q4 25 | $176.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $157.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $880.7M | $-80.0M | ||
| Q3 25 | $870.9M | $9.2M | ||
| Q2 25 | $839.4M | $151.3M | ||
| Q1 25 | $788.6M | $144.2M | ||
| Q4 24 | $744.9M | $255.0M | ||
| Q3 24 | $778.5M | $346.8M | ||
| Q2 24 | $717.1M | $432.4M | ||
| Q1 24 | $708.1M | $140.3M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B | ||
| Q1 24 | $1.3B | $1.3B |
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $146.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $145.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 37.5% | -48.6% |
| 资本支出强度资本支出/营收 | 0.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.21× | — |
| 过去12个月自由现金流最近4个季度 | $190.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $146.5M | $-99.8M | ||
| Q3 25 | $63.9M | $-91.4M | ||
| Q2 25 | $11.9M | $-108.3M | ||
| Q1 25 | $-7.4M | $-166.5M | ||
| Q4 24 | $138.0M | $-79.3M | ||
| Q3 24 | $76.1M | $-67.0M | ||
| Q2 24 | $25.5M | $-77.0M | ||
| Q1 24 | $-52.0M | $-190.7M |
| Q4 25 | $145.0M | $-100.8M | ||
| Q3 25 | $57.6M | $-92.7M | ||
| Q2 25 | $-3.3M | $-110.7M | ||
| Q1 25 | $-8.8M | $-167.8M | ||
| Q4 24 | $136.1M | $-79.5M | ||
| Q3 24 | $75.4M | $-68.6M | ||
| Q2 24 | $24.4M | $-79.0M | ||
| Q1 24 | $-53.0M | $-193.9M |
| Q4 25 | 37.5% | -48.6% | ||
| Q3 25 | 13.4% | -58.0% | ||
| Q2 25 | -1.0% | -66.5% | ||
| Q1 25 | -2.6% | -120.5% | ||
| Q4 24 | 37.7% | -48.3% | ||
| Q3 24 | 17.8% | -49.2% | ||
| Q2 24 | 7.1% | -53.7% | ||
| Q1 24 | -16.4% | -178.2% |
| Q4 25 | 0.4% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 4.5% | 1.5% | ||
| Q1 25 | 0.4% | 1.0% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.3% | 1.4% | ||
| Q1 24 | 0.3% | 3.0% |
| Q4 25 | 5.21× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | -0.17× | — | ||
| Q4 24 | 5.69× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | -1.27× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IPAR
| European Based Operations | $232.7M | 60% |
| United States Based Operations | $155.2M | 40% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
